Physician profile
Eric B Anderson
NPI 1891741757
$2,165.67
in general payments reported to CMS, 2019-2025
35 companies · $463 in 2025
The $463 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2020: $187 · 2021: $567 · 2022: $257 · 2023: $218 · 2024: $259 · 2025: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $896 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $896.36 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $362.02 | 2020-2025 | |
| Daiichi Sankyo INC. | $180.31 | 2019-2025 | Injectafer, Datroway |
| Amgen INC. | $160.66 | 2019-2023 | Kyprolis, Blincyto |
| Pfizer INC. | $144.01 | 2021-2025 | |
| Exelixis INC. | $126.78 | 2019-2025 | Cabometyx |
| Celgene Corporation | $115.58 | 2019-2023 | Reblozyl |
| Merck Sharp & Dohme LLC | $105.43 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $80.53 | 2024-2025 | Enhertu, Calquence, Imfinzi |
| Glaxosmithkline, LLC. | $75.99 | 2021 | |
| Amag Pharmaceuticals, INC. | $75.67 | 2019-2021 | |
| Eisai INC. | $74.00 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $71.67 | 2020-2022 | |
| Fennec Pharmaceuticals, INC. | $47.62 | 2025 | Fyarro |
| Beigene USA, INC. | $44.99 | 2023-2024 | Brukinsa |
| Alexion Pharmaceuticals, INC. | $44.85 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.65 | 2021-2023 | Gilotrif |
| Array Biopharma INC | $39.42 | 2021 | |
| Sumitomo Pharma America, INC. | $36.86 | 2025 | Orgovyx |
| Genzyme Corporation | $36.59 | 2019-2023 | |
| Janssen Biotech, INC. | $35.94 | 2024-2025 | Darzalex, Tecvayli |
| Regeneron Healthcare Solutions, INC. | $33.19 | 2021 | |
| Abbott Laboratories | $23.45 | 2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Clovis Oncology, INC. | $21.70 | 2019 | |
| Seagen INC. | $21.43 | 2021 | |
| Sobi, INC | $21.02 | 2025 | |
| Abbvie INC. | $19.64 | 2024 | |
| Pharmacosmos Therapeutics INC. | $19.47 | 2023 | Monoferric |
| G1 Therapeutics, INC. | $18.86 | 2022 | |
| Lilly USA, LLC | $16.08 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.32 | 2023 | |
| Geron Corporation | $14.25 | 2025 | Rytelo |
| Dova Pharmaceuticals | $14.03 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Taiho Oncology, INC. | $11.74 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.